Equillium (EQ) Accounts Payables (2017 - 2026)
Equillium (EQ) reported Accounts Payables of $1.3 million for Q1 2026, down 57.65% year-over-year from $3.1 million in Q1 2025, and up 71.52% on a QoQ basis from $755000.0 in Q4 2025.
Equillium (EQ) has 10 years of Accounts Payables data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Accounts Payables fell 57.65% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 57.65% YoY) and the FY2025 annual result came in at $755000.0, down 71.79% from the prior year.
- Accounts Payables rose to $1.3 million in Q1 2026 per EQ's latest filing, from $755000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.7 million in Q1 2023 and bottomed at $755000.0 in Q4 2025.
- The 5-year median for Accounts Payables is $3.6 million (2023), against an average of $3.4 million.
- The widest annual swing landed in 2022, when Accounts Payables surged 224.65%; it then slumped 71.79% in 2025.
- Tracing EQ's Accounts Payables over 5 years: stood at $4.0 million in 2022, then gained by 18.36% to $4.7 million in 2023, then sank by 43.15% to $2.7 million in 2024, then tumbled by 71.79% to $755000.0 in 2025, then jumped by 71.52% to $1.3 million in 2026.
- Per Business Quant, the three latest EQ Accounts Payables figures stand at $1.3 million (Q1 2026), $755000.0 (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 755,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 4.71 Mn |
| Sep 30, 2023 | 3.64 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 3.98 Mn |
| Sep 30, 2022 | 2.47 Mn |
| Jun 30, 2022 | 5.09 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 2.67 Mn |
| Jun 30, 2021 | 1.82 Mn |
| Mar 31, 2021 | 2.32 Mn |
| Dec 31, 2020 | 2.77 Mn |
| Sep 30, 2020 | 1.68 Mn |
| Jun 30, 2020 | 1.76 Mn |
| Mar 31, 2020 | 1.80 Mn |
| Dec 31, 2019 | 1.87 Mn |
| Sep 30, 2019 | 2.68 Mn |
| Jun 30, 2019 | 1.97 Mn |
| Mar 31, 2019 | 1.59 Mn |
| Dec 31, 2018 | 1.12 Mn |
| Sep 30, 2018 | 1.23 Mn |
| Dec 31, 2017 | 243,741.00 |